Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 23327570)

1.

A frequent gene polymorphism affecting the heart-rate response to carvedilol.

Eschenhagen T.

Pharmacogenomics. 2013 Jan;14(2):115-8. doi: 10.2217/pgs.12.198. No abstract available.

2.

Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.

Rau T, Düngen HD, Edelmann F, Waagstein F, Lainščak M, Dimković S, Apostolović S, Nešković AN, Haverkamp W, Gelbrich G, Eschenhagen T.

Clin Pharmacol Ther. 2012 Jul;92(1):21-8. doi: 10.1038/clpt.2012.18. Epub 2012 May 23. Erratum in: Clin Pharmacol Ther. 2012 Sep;92(3):397.

PMID:
22617224
3.

[A fairer comparison between carvedilol and metoprolol is still to be done].

Johnsson G, Aberg J.

Lakartidningen. 2003 Oct 30;100(44):3543-4, 3544-5. Swedish. No abstract available.

PMID:
14651018
4.

Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.

Metra M, Covolo L, Pezzali N, Zacà V, Bugatti S, Lombardi C, Bettari L, Romeo A, Gelatti U, Giubbini R, Donato F, Dei Cas L.

Cardiovasc Drugs Ther. 2010 Feb;24(1):49-60. doi: 10.1007/s10557-010-6220-5.

PMID:
20352314
5.

Dismantling mandates in the treatment of heart failure.

Leier CV.

J Am Coll Cardiol. 2004 Nov 2;44(9):1831-3. No abstract available.

6.

A comment on COMET: how to interpret a positive trial?

Massie BM.

J Card Fail. 2003 Dec;9(6):425-8. No abstract available.

PMID:
14966781
7.

Role of carvedilol in atrial fibrillation: insights from clinical trials.

Gheorghiade M, Lukas MA.

Am J Cardiol. 2004 May 6;93(9A):53B-7B. Review.

PMID:
15144939
8.

Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure.

Piccirillo G, Luparini RL, Celli V, Moisè A, Lionetti M, Marigliano V, Cacciafesta M.

Am J Cardiol. 2000 Dec 15;86(12):1392-5, A6.

PMID:
11113424
9.

Heart failure patients with B1-adrenoreceptor polymorphisms have augmented carvedilol response as detected by cardiac I123-MIBG scintigraphy.

Miranda SM, Moscavitch SD, Pereira SB, de Azevedo JC, Messias LR, Rodrigues RC, Mesquita ET, Ribeiro GS, Mesquita CT.

Int J Cardiol. 2014 Nov 15;177(1):111-3. doi: 10.1016/j.ijcard.2014.09.064. Epub 2014 Sep 28. No abstract available.

PMID:
25499350
10.

Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.

Marazzi G, Iellamo F, Volterrani M, Caminiti G, Madonna M, Arisi G, Massaro R, Righi D, Rosano GM.

Am J Cardiol. 2011 Jan 15;107(2):215-9. doi: 10.1016/j.amjcard.2010.08.062. Epub 2010 Dec 2.

PMID:
21129714
11.

Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol.

Troncoso R, Moraga F, Chiong M, Roldán J, Bravo R, Valenzuela R, Díaz-Araya G, del Campo A, Sanhueza C, Rodriguez A, Vukasovic JL, Mellado R, Greig D, Castro PF, Lavandero S.

Basic Clin Pharmacol Toxicol. 2009 May;104(5):374-8.

PMID:
19422106
12.

[A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].

Torp-Pedersen CT; Carvedilol Or Metoprolol European Trial.

Ugeskr Laeger. 2004 Aug 2;166(32):2671-4. Danish. No abstract available.

PMID:
15347171
13.

Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.

Chen L, Meyers D, Javorsky G, Burstow D, Lolekha P, Lucas M, Semmler AB, Savarimuthu SM, Fong KM, Yang IA, Atherton J, Galbraith AJ, Parsonage WA, Molenaar P.

Pharmacogenet Genomics. 2007 Nov;17(11):941-9.

PMID:
18075464
14.

Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.

Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, Libhaber C, Sareli P, Essop R.

J Am Coll Cardiol. 2004 Nov 2;44(9):1825-30.

15.

[Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol].

Tepliakov AT, Shilov SN, Berezikova EN, Torim IuIu, Efremov AV, Safronov ID, Maianskaia SD, Popova AA, Voronina EN, Karpov RS.

Ter Arkh. 2010;82(12):22-8. Russian.

PMID:
21516734
16.

[The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].

Swedberg K.

Lakartidningen. 2003 Sep 11;100(37):2852-4. Swedish. No abstract available.

PMID:
14558169
17.

Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.

Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR.

Eur J Heart Fail. 2013 Mar;15(3):324-33. doi: 10.1093/eurjhf/hfs181. Epub 2012 Dec 7.

18.

Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?

Cioffi G, De Feo S, Pulignano G, Del Sindaco D, Tarantini L, Stefenelli C, Opasich C.

Int J Cardiol. 2006 Feb 15;107(2):220-4.

PMID:
16412800
19.

Carvedilol prevents severe hypertensive cardiomyopathy and remodeling.

Barone FC, Campbell WG Jr, Nelson AH, Feuerstein GZ.

J Hypertens. 1998 Jun;16(6):871-84.

PMID:
9663928
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk